Clin Case Rep Int | Volume 4, Issue 1 | Rapid Communication | Open Access
Mazzucato M1, Garelli S1, Presotto F2, Betterle C3 and De Riva C1*
1Department of Endocrine and Metabolic Diseases, Mestre Hospital, Italy 2Department of Internal Medicine, Mestre Hospital, Italy 3Department of Endocrinology, Padua University, ItalyFulltext PDF
Background: Immune checkpoint inhibitors are new cancer drugs that act stimulating immune adapted response of patient to obtain tumor regression. Immunotherapy can generate immunerelated adverse events involved all organs, in particular checkpoint inhibitors PD1/PDL1 can develop autoimmune type 1 diabetes. Case Presentation: A 64 years old man affected by metastatic non-small cell lung carcinoma, after conventional therapy, was treated with pembrolizumab (a PD1/PDL1 checkpoint inhibitor): After ten weeks, he showed hyperglycemia with ketosis, stable reduced c-peptide, and positive anti-glutamic acid decarboxylase antibodies therefore he was treated with insulin injection. The histological image of pancreas appeared like an immune-mediated insulitis. Conclusion: New guidelines are recently published to inform clinicians and patients about frequent immune adverse events of these new immunotherapies.
Mazzucato M, Garelli S, Presotto F, Betterle C, De Riva C. Checkpoint Inhibitor Develops Histological Autoimmune Pancreatitis Like Type 1 Diabetes: a Case Report. Clin Case Rep Int. 2020; 4: 1156.